STOCK TITAN
  1. Home
  2. News
  3. INMB

INmune Bio Inc - INMB STOCK NEWS

Welcome to our dedicated news page for INmune Bio (Ticker: INMB), a resource for investors and traders seeking the latest updates and insights on INmune Bio.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect INmune Bio's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of INmune Bio's position in the market.

News
INmune Bio Announces FDA Removal of Clinical Hold for Alzheimer’s Disease Program
Rhea-AI Summary
INmune Bio Inc. (INMB) has received confirmation from the FDA that the full clinical hold on the Company’s Alzheimer’s disease (AD) clinical trial program has been lifted. The Phase II trial is on track to enroll the last patient mid-2024, with top line data expected approximately six months after the last patient is enrolled. CEO RJ Tesi expressed satisfaction with the FDA's response and outlined the company's goals for the Phase III AD program.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-7.52%
Tags
none
-
News
INmune Bio Announces First Patient Dosed in a Phase 1/2 Study of INKmune™ in Patients with Metastatic Castration-Resistant Prostate Cancer
Rhea-AI Summary
INmune Bio, Inc. (NASDAQ: INMB) dosed the first patient in the Phase I/II trial for INKmune™, a biologic therapy for metastatic castration-resistant prostate cancer (mCRPC), on December 27, 2023. The therapy aims to harness the patient’s innate immune system to fight disease, with promising potential in targeting NK cells abundant in the tumor microenvironment. Professor Matt Rettig, a leading expert, expressed optimism in this novel strategy.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.36%
Tags
clinical trial
-
News
INmune Bio Provides Update Regarding Global Alzheimer’s Phase II Clinical Trial and Clinical Hold Issued by the United States FDA
Rhea-AI Summary
INmune Bio Inc. (NASDAQ: INMB) is accelerating enrollment in its Phase II study using XProTM to treat patients with Alzheimer’s Disease with neuroinflammation outside the US, maintaining its timeline for the trial. However, the Phase II study remains on clinical hold in the US pending additional information on long-term stability, with the Company expecting to provide the necessary data before the end of 2023. The Company is on track to complete enrollment of its Phase II clinical trial in patients with early Alzheimer’s Disease and biomarkers of inflammation in 2024. The trial is open in Australia, Canada, the United Kingdom, Poland, France, Spain, and is expected to open soon in several additional EU countries.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-9.29%
Tags
clinical trial
News
INmune Bio Inc. Demonstrates that INB03 Enhances the Uptake of Trastuzumab Deruxtecan in HER2+ Breast Cancer with MUC4 Expression in Poster Presented at San Antonio Breast Cancer Symposium
Rhea-AI Summary
INmune Bio, Inc. (NASDAQ: INMB) presents data on the use of INB03, a dominant-negative TNF inhibitor, to improve the potency of trastuzumab deruxtecan (T-DXd, ENHERTU®) in the treatment of high-risk MUC4 expressing HER2 positive breast cancer. The work demonstrates that INB03 decreases resistance to T-DXd therapy in three ways, suggesting that it may allow for lower doses of T-DXd to be effective in women with MUC4 expressing HER2+ breast cancer and improve the response to T-DXd in women with resistant HER2+ disease.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.49%
Tags
none
-
News
INmune Bio Receives EMA’s Authorization in France and Spain for Phase II Clinical Trial of XPro™ for Early Alzheimer’s Disease
Rhea-AI Summary
INmune Bio, Inc. (INMB) has received authorization from the European Medicines Agency (EMA) to initiate a Phase II trial in Early Alzheimer’s Disease (AD) with XPro™. The trial is currently enrolling patients in Australia, Canada, the United Kingdom, France, and Spain. The Phase II clinical trial is a global, multi-center, randomized clinical study in patients diagnosed with early Alzheimer's disease who have biomarkers of elevated inflammation. In a prior Phase I open-label trial, INmune Bio met all primary and secondary endpoints. Patients with AD who received XPro™ demonstrated notable decreases in neuroinflammation, enhanced axonal integrity, and improved synaptic function.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.64%
Tags
clinical trial
-
News
INmune Bio Inc. Announces Expansion of Phase II Clinical Trial for Alzheimer’s Disease in Europe
Rhea-AI Summary
INmune Bio, Inc. (NASDAQ: INMB) has received regulatory approval to extend its Phase II trial of XPro™ in individuals with early Alzheimer’s disease in Poland, with additional EU countries expected to open soon. The company also received a cash refund of approximately $2.8M USD pursuant to an Australian Research and Development Tax Incentive.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.94%
Tags
clinical trial
News
INmune Bio Inc. Announces Third Quarter 2023 Results and Provides Business Update
Rhea-AI Summary
INmune Bio Inc. announces Q3 2023 financial results and provides business update. Highlights include authorization to initiate a Phase II trial for XPro™ in Early Alzheimer's Disease, expansion of MRI biomarker data, and positive preclinical data for INB03. Net loss for Q3 2023 was $8.6 million. The company had cash and cash equivalents of $41.8 million as of September 30, 2023.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.82%
Tags
earnings
-
News
INmune Bio Inc. Patent Claims Covering INB16 Cell Line and INKmune™ Therapeutic Composition given Favorable Patentability Opinion by International Search Authority
Rhea-AI Summary
INmune Bio, Inc. receives a favorable patentability opinion for its international patent application covering its proprietary cell line, INB16, and the therapeutic composition INKmune™. The application contains patentable subject matter and explores potential commercial applications in cancer research and treatment. The company plans to leverage the opinion to accelerate examination and patent issuance. INB16 is a tumor cell line that can prime natural killer (NK) cells to enhance their ability to fight cancer. The company has safely treated five patients with hematological cancers using INKmune™ and plans to initiate a US trial in metastatic castration-resistant prostate cancer.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
7.84%
Tags
none
-
News
INmune Bio Inc. Presents Preclinical Data at SITC 2023 Showing INB03 is an Innate Immune Check Point Inhibitor that Downregulates SIRPα
Rhea-AI Summary
INmune Bio, Inc. is presenting data on the use of INB03, a dominant-negative inhibitor of soluble TNF, in the treatment of high-risk MUC4 expressing HER2+ breast cancer. INB03 is an innate immune checkpoint inhibitor working through the SIRPα-CD47 pathway to promote ADCP. The research shows that INB03 downregulates SIRPα expression to eliminate the 'don’t eat me signal' and promote ADCP.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.73%
Tags
clinical trial
News
Cumulus Neuroscience Presents Data at CTAD 2023 Annual Meeting
Rhea-AI Summary
Cumulus Neuroscience presented data at the Clinical Trials on Alzheimer's Disease (CTAD) Annual Meeting, validating the utility of their Cumulus Neuroassessment Platform in clinical studies for patients with mild to moderate cognitive impairment. The data showed that the platform can be used by patients with Alzheimer's Disease over long periods of time, even at home. The findings also demonstrated that digital technologies have construct validity and can measure change in dementia-relevant cognitive functions. Cumulus aims to accelerate Alzheimer's clinical studies by capturing longitudinal electrophysiological correlates of the disease in decentralized trials.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.56%
Tags
none
Stock INMB logo
INmune Bio Inc

Nasdaq:INMB

INMB Rankings

#3758 Ranked by Market Cap
#2639 Ranked by Stock Gains
N/A Ranked by Dividends

INMB Stock Data

187.30M
11.74M
34.91%
13.83%
8.47%
Research and Development in Biotechnology
Professional, Scientific, and Technical Services
Link
United States
Boca Raton

About INMB

inmune bio inc. is a clinical stage immuno-oncology company focused on harnessing the patient’s immune system to treat cancer. inkmune, the company’s lead product, primes patient’s nk cells (natural killer cells) to kill cancer. inmune is targeting residual disease, the cancer cells that survive initial treatments that return to cause the cancer relapse. by controlling residual disease, patients may live longer. using a novel mechanism of action and a precision medicine approach, inkmune therapy should enhance nk cells’ ability to eliminate residual disease.